XML 58 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Note 12 - Contingently Redeemable Noncontrolling Interests (Details Textual)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jun. 13, 2022
USD ($)
shares
Nov. 12, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
shares
Jun. 30, 2022
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2020
USD ($)
Temporary Equity, Accretion to Redemption Value         $ 0 $ 200  
SEED Therapeutics Inc. [Member]              
Share Price (in dollars per share) | $ / shares   $ 7.5375          
Proceeds from Issuance Initial Public Offering   $ 50,000          
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Forward Contract [Member]              
Derivative Asset $ 1,237            
Series A-2 Preferred Shares [Member] | Research Collaboration and License Agreement with Eli Lilly [Member]              
Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value 3,763           $ 5,267
Series A-2 Preferred Shares [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]              
Annual Return, Percentage   8.00%          
Number of Annual Redemption Installments   3          
Stock Issued During Period, Value, New Issues $ 5,000     $ 1,990,000      
Stock Issued During Period, Shares, New Issues (in shares) | shares 1,990,000 1,990,000 1,990,000